Video Experimental Relacionado
Updated: Jul 19, 2026
10:18
Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
El polimorfismo de inserción/deleción del gen de la enzima convertidora de angiotensina y la respuesta al
H Montgomery1, P Clarkson, M Barnard
1Centre for Cardiovascular Genetics, University College London, Rayne Institute, UK. h.montgomery@ucl.ac.uk
Lancet (London, England)
|February 24, 1999
Resumen
Los individuos con el genotipo II, que indica una menor actividad de la enzima convertidora de angiotensina (ECA), mostraron mayores ganancias de masa muscular y grasa durante el ejercicio intenso. Esto sugiere una mayor eficiencia metabólica y una mejor respuesta al entrenamiento.
Área de la Ciencia:
- Fisiología del ejercicio fisiológico.
- Genética humana Genética humana es la genética humana.
- Estudios sobre el metabolismo.
Sus antecedentes:
- El papel de los sistemas locales de renina-angiotensina en el músculo esquelético y el tejido adiposo es poco conocido.
- Un polimorfismo común en el gen de la enzima convertidora de angiotensina humana (ACE) (inserción / eliminación) influye en la actividad de la ACE y la respuesta al entrenamiento.
Objetivo del estudio:
- Investigar la asociación entre el polimorfismo de inserción/deleción del gen ACE y los cambios en la composición corporal.
- Para explorar los efectos metabólicos de los sistemas locales de renina-angiotensina durante el ejercicio intensivo.
Principales métodos:
- Tres métodos independientes (bioimpedancia, grosor del pliegue cutáneo, resonancia magnética) evaluaron los cambios en la composición corporal.
- El estudio involucró a jóvenes reclutas masculinos del ejército que se sometieron a 10 semanas de entrenamiento físico intensivo.
Principales resultados:
- El grupo del genotipo II exhibió una respuesta anabólica significativamente mayor en masa grasa (0,55 kg) y masa no grasa (1,31 kg) en comparación con los grupos con alelos D.
- Los cambios en la morfología corporal durante el entrenamiento dependieron del genotipo ACE.
Conclusiones:
- El genotipo II, vinculado a una menor actividad ACE, puede promover un equilibrio energético positivo y una mayor eficiencia metabólica durante el entrenamiento riguroso.
- Este hallazgo podría explicar los beneficios observados con las terapias con inhibidores de la ECA.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...